Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine versus sufentanil PCIA after thoracoscopic lung resection for prevention of chronic postsurgical pain
ChiCTR2500104087Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine and sufentanil in Persistent postsurgical pain (PPSP) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Incidence of chronic postsurgical pain at 3 months after surgery. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
oliceridinesufentanil
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on ChiCTR2500104087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104087.